Tuesday, Aug 04, 2020 | Last Update : 03:50 PM IST

133rd Day Of Lockdown

Maharashtra45019628703015842 Tamil Nadu2632222022834241 Andhra Pradesh166586886781537 Karnataka139571625002594 Delhi1384821242544021 Uttar Pradesh97362553931778 West Bengal78232548181731 Telangana6766048609551 Gujarat64684476632504 Bihar5956738508336 Rajasthan4555532051719 Assam4527633429109 Haryana3717330470440 Odisha3629723074248 Madhya Pradesh3428524099900 Kerala268731527885 Jammu and Kashmir2200614032407 Punjab1852711882442 Jharkhand135004794125 Chhatisgarh9820725661 Uttarakhand7800453890 Goa6816487656 Tripura5389360527 Puducherry3982241156 Manipur292017667 Himachal Pradesh2818165813 Nagaland21296574 Arunachal Pradesh175810633 Chandigarh116070619 Meghalaya9022645 Sikkim6882971 Mizoram4962660
  Science   03 Jul 2020  Zydus Cadila's potential covid drug may begin human clinical trials

Zydus Cadila's potential covid drug may begin human clinical trials

PTI
Published : Jul 3, 2020, 11:01 am IST
Updated : Jul 3, 2020, 11:01 am IST

India’s 'first' indigenous COVID-19 vaccine candidate Covaxin had also got the nod for human clinical trials recently

 Representational Image. (AP)
  Representational Image. (AP)

New Delhi: A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials, according to a government source.

The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

 

"DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd on Thursday after its animal studies were found to be successful," an official source in the know of the developments told PTI.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, the source said.

The company is likely to start enrolment of subjects soon.

"The phase I and II trials will take around three months to be completed," the source said.

 

The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

India's COVID-19 tally rose to 6,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the death toll rose to 17,834 with 434 new fatalities, according to the Union Health Ministry.

Tags: covaxin, hyderabad, bharat biotech, zydus cadila healthcare ltd, ahmedabad, drugs controller general of india (dcgi), human trial, covid-19 vaccine, coronavirus, indian vaccine
Location: India, Delhi, New Delhi